GUTS
What one share of Fractyl Health holds
Surgical and Medical Instruments and Apparatus
We are a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (“T2D”). Our Revita® and Rejuva® candidates are designed to target root causes of metabolic diseases, allowing us to advance metabolic disease treatment from chronic management towards prevention and reversion of the disease.
Fractyl Health’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.81 |
|---|---|
| Cash and investments | $0.30 |
| Debt | $0.19 |
| Book value | −$0.01 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | $0.06 | −$45.29 | $0.17 | −$20.75 | — | −$154.36 |
| 2024 | $0.00 | −$1.62 | $0.04 | −$1.55 | — | $0.58 |
| 2025 | $0.00 | −$1.86 | $0.01 | −$1.20 | — | $0.06 |